Shuttle Pharmaceuticals Holdings, Inc. — Form 8-K
Filed September 1, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Shuttle Pharmaceuticals (acquiror) and United Dogecoin Inc. (acquired company) executed a First Amendment to their April 30, 2026 Merger Agreement, effective August 31, 2026. The amendment modifies the definition of 'Milestone Event' in Section 3.07b by reducing a numerical threshold from 2,000 to 500 in clause (i). No dollar amounts, payment terms, or business rationale are disclosed in this filing.
Why this rating
Amendment details are vague—no financials, deal value, or business impact disclosed. Threshold reduction suggests easier milestone achievement (favorable to Shuttle), but without context on what the milestone measures or payment implications, materiality cannot be assessed. Routine amendment disclosure relative to $4.7M cap.
See more from September 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.